Temozolomide, an alkylating agent, initially used in the treatment of gliomas was expanded
to include pituitary tumors in 2006. After 12 years of use, temozolomide has shown a notable …

Pituitary adenomas are considered benign tumors, but approximately 10% of them can have
an aggressive behavior and more rarely (0.2%) can present metastasis, being classified as …

Background Most pituitary neuroendocrine tumors (PitNETs) show benign behavior, but a
substantial number are invasive, recur, or resist medical treatment. Based on a retrospective …

Context: Despite the major risk of regrowth of clinically nonfunctioning pituitary adenomas
(CNFAs) after primary treatment, systematic data on the probability of further tumor …

Comprehensive investigations on the incidence and prognosis of pituitary tumors are still
lacking. The present study aims to summarize the incidence, demographics, and survival …

The deregulation of transcription and processing of microRNAs (miRNAs), as well as their
function, has been involved in the pathogenesis of several human diseases, including …

Pituitary adenomas are unique in multiple ways. They are rarely malignant in terms of
metastases; yet, they may be aggressive. Their cancerous potential is defined in a classic …

Pituitary adenomas are common neoplasms. Their classification is based upon size,
invasion of adjacent structures, sporadic or familial cases, biochemical activity, clinical …

Pituitary tumors are very complex and heterogeneous and have a very wide range of
proliferative and aggressive behaviors, and how to define and classify these tumors remains …

Background Personalized postoperative management of patients with pituitary adenomas
requires an early risk stratification system. Methods We reviewed 501 cases operated …